Adage Capital Partners
SLDB icon

Adage Capital Partners’s Solid Biosciences SLDB Stock Holding History

Adage Capital Partners’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15M Sell
1,506,506
-250,000
-14% -$1.9M 0.02% 596
2026
Q1 		$12.6M Buy
1,756,506
+356,506
+25% +$2.29M 0.02% 633
2025
Q4 		$7.9M Sell
1,400,000
-2,600,000
-65% -$14.1M 0.01% 706
2025
Q3 		$24.7M Sell
4,000,000
-2,729,484
-41% -$16M 0.04% 406
2025
Q2 		$32.8M Hold
6,729,484
– – 0.06% 323
2025
Q1 		$24.9M Buy
6,729,484
+4,981,400
+285% +$21.3M 0.05% 367
2024
Q4 		$6.99M Sell
1,748,084
-6,075
-0.3% -$33.4K 0.01% 674
2024
Q3 		$12.2M Sell
1,754,159
-200,000
-10% -$1.62M 0.02% 572
2024
Q2 		$11.1M Sell
1,954,159
-584,738
-23% -$5.24M 0.02% 580
2024
Q1 		$33.8M Buy
+2,538,897
New +$23.8M 0.06% 323
2019
Q4 		– Sell
-32,800
Closed -$5.09M – 757
2019
Q3 		$5.09M Buy
+32,800
New +$3.71M 0.01% 626
2018
Q4 		– Sell
-9,333
Closed -$6.61M – 747
2018
Q3 		$6.61M Sell
9,333
-7,334
-44% -$4.61M 0.01% 606
2018
Q2 		$8.91M Sell
16,667
-20,000
-55% -$6.15M 0.02% 583
2018
Q1 		$4.13M Buy
+36,667
New +$12.4M 0.01% 654

Other funds holding SLDB

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Adage Capital Partners's SLDB Position: Q2 2026 in Review

Adage Capital Partners reduced its Solid Biosciences (SLDB) stake by 14% in Q2 2026, selling an estimated $1.9M and leaving 1,506,506 shares worth $15M. The position accounts for 0.02% of the portfolio, ranked #596.

Adage Capital Partners first reported a position in SLDB in Q1 2018 and has held it in 14 quarters since. The position peaked at $33.8M in Q1 2024. 157 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

  • Adage Capital Partners held 1,506,506 shares of Solid Biosciences worth $15M as of Q2 2026.
  • Adage Capital Partners sold 250,000 Solid Biosciences shares in Q2 2026, an estimated $1.9M.
  • Solid Biosciences made up 0.02% of Adage Capital Partners's portfolio in Q2 2026, its #596 holding.
  • Adage Capital Partners first reported a position in Solid Biosciences in Q1 2018 and has held it in 14 quarters since.
  • Adage Capital Partners's Solid Biosciences position peaked at $33.8M in Q1 2024.
  • 157 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.